文献速递外周动脉疾病

编辑推荐——严重下肢缺血血运重建策略比较(BASIL)-2试验:膝下静脉旁路术或最佳血管内治疗优先血运重建策略随机受试者死亡时间与原因分析

Editor's Choice - Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL)-2 Trial: Analysis of the Timing and Causes of Death in Participants Randomised to an Infrapopliteal Vein Bypass or Best Endovascular Treatment First Revascularisation Strategy.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2024-07-26

BASIL-2试验纳入需膝下(伴或不伴股腘)血运重建的慢性肢体威胁性缺血患者,随机至静脉旁路(VB)优先策略者全因死亡风险较最佳血管内治疗(BET)优先策略高逾三分之一。本研究采用改良德尔菲共识判定死亡原因,发现VB组心源性死亡比例高于BET组,超额死亡主要归因于心源性死亡且贯穿随访全程。

要点

  • VB优先策略全因死亡风险较BET优先策略高逾三分之一,中位随访40.0个月。
  • 德尔菲小组对168例死亡中151例(89.9%)达成死亡原因共识。
  • BET组心源性死亡16/77例(21%),VB组32/91例(35%),未校正亚分布HR 2.16。

核心结论

  • BASIL-2中VB优先血运重建策略组观察到的超额死亡主要归因于德尔菲小组判定为可能主要心源性的死亡,这些超额心源性死亡贯穿随访全程且无证据提示非比例风险。

研究设计与样本

  • BASIL-2试验纳入需膝下(伴或不伴股腘)血运重建的慢性肢体威胁性缺血患者,随机至静脉旁路(VB)优先或最佳血管内治疗(BET)优先策略。
  • 本分析由10人国际小组(血管与血管内外科医生及血管介入放射科医生,均为BASIL-2主要研究者)采用改良德尔菲共识判定主要死亡原因及是否主要心源性。

主要发现

  • 168例死亡中151例(89.9%)德尔菲小组就死亡原因可能为心源性或非心源性达成共识。
  • BET组77例死亡中16例(21%)判定为可能心源性,VB组91例中32例(35%),未校正亚分布风险比2.16(95%CI 1.20-3.87),未校正病因特异性风险比2.15(95%CI 1.19-3.90)。
  • 随机化时344例中64例(18.6%)有既往心肌梗死,342例中40例(11.7%)有既往经皮冠状动脉介入治疗,344例中37例(10.8%)有既往冠状动脉旁路移植术。
  • 既往经皮冠状动脉介入治疗、冠状动脉旁路移植术或心肌梗死亚组分析中无证据显示死亡原因的治疗效应存在差异。

关键数值与推荐

  • VB优先策略组全因死亡风险较BET优先策略组高逾三分之一,中位随访40.0个月(四分位距20.9-60.6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL)-2 trial enrolled participants with chronic limb threatening ischaemia who required an infrapopliteal, with or without a femoropopliteal, revascularisation procedure to restore limb perfusion. Participants randomised to a vein bypass (VB) first revascularisation strategy were over one third more likely than those randomised to a best endovascular treatment (BET) first revascularisation strategy to die from any cause during a median follow up of 40.0 (interquartile range 20.9, 60.6) months. The aim of the present study was to describe the timing and causes of death in BASIL-2 as a first step towards trying to better understand why randomisation to a VB first revascularisation strategy was associated with this excess mortality. METHODS: A 10 person international panel comprising vascular and endovascular surgeons as well as vascular interventional radiologists, who had all been principal investigators in BASIL-2, took part in a modified Delphi consensus exercise to adjudicate the primary cause of death and, in particular, whether the cause was primarily cardiac or non-cardiac. RESULTS: In 151 of 168 deaths (89.9%), the Delphi panel achieved a consensus regarding the cause of death being probably cardiac or non-cardiac. In the BET group, 16 of 77 deaths (21%) were classified as probably cardiac compared with 32 of 91 (35%) in the VB group (unadjusted subdistribution hazard ratio 2.16, 95% confidence interval [CI] 1.20 - 3.87; unadjusted cause specific hazard ratio 2.15, 95% CI 1.19 - 3.90). At the point of randomisation, 64 of 344 (18.6%), 40 of 342 (11.7%), and 37 of 344 (10.8%) participants had a previous myocardial infarction (MI), percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG), respectively. There was no evidence of varying treatment effects for cause of death in subgroup analyses of previous PCI, CABG, or MI. CONCLUSION: The excess mortality observed in the VB first revascularisation strategy group in BASIL-2 was largely due to deaths that were adjudicated by the Delphi panel as probably primarily cardiac. These excess cardiac deaths were observed throughout follow up and there was no evidence of non-proportional hazards. Further work is ongoing to try to better understand the reasons for these findings.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bradbury AW, Hall J, Moakes CA, et al. Editor's Choice - Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL)-2 Trial: Analysis of the Timing and Causes of Death in Participants Randomised to an Infrapopliteal Vein Bypass or Best Endovascular Treatment First Revascularisation Strategy. Eur J Vasc Endovasc Surg. 2024. PMID: 39069068. doi:10.1016/j.ejvs.2024.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。